Global burden of viral infectious diseases of poverty based on GBD 2021 DOI Creative Commons

Xinchen LI,

Yanyan Zhang,

Qiyu ZHANG

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Июнь 19, 2024

Abstract Background Viral infectious diseases of poverty (vIDPs) remain a significant global health challenge. Despite their profound impact, the burden these is not comprehensively quantified. This study aims to analyze six major vIDPs, including COVID-19, HIV/AIDS, acute hepatitis, dengue, rabies, and Ebola, by using data from Global Burden Diseases, Injuries, Risk Factors Study 2021 (GBD 2021). Methods Following methodological framework analytical strategies GBD 2021, we analyzed incidence, mortality, disability-adjusted life years (DALYs) vIDPs across 204 countries territories 1990 2021. We also examined association between Socio-Demographic Index (SDI) vIDPs. All estimates were reported as numbers rates per 100,000 population, with 95% uncertainty intervals (UI). Results In total deaths due approximately 8.7 million, DALYs 259.2 accounting for 12.8% 9.0% all-cause totals, respectively. Globally, varied significantly. COVID-19 was most impactful, 7.9 million (95% UI 7.5-8.4) 212.0 197.9-234.7) in Acute hepatitis had second-highest age-standardized incidence rate, while HIV/AIDS high prevalence rate. The dengue significantly increased, cases rising 26.5 3.9-51.9) 59.0 15.5-106.9) Rabies, although reduced prevalence, continued pose mortality risk. Ebola lowest overall but showed impacts during outbreaks. Analysis revealed negative correlation SDI whereas no direct SDI. Conclusions public challenges worldwide, regional, age, gender disparities. results underscore need targeted interventions international cooperation mitigate diseases. Policymakers can use findings implement cost-effective improve outcomes, particularly regions or increasing burdens.

Язык: Английский

Global burden of metabolic diseases, 1990–2021 DOI
Huai Zhang, Xiaodong Zhou, Michael D. Shapiro

и другие.

Metabolism, Год журнала: 2024, Номер 160, С. 155999 - 155999

Опубликована: Авг. 14, 2024

Язык: Английский

Процитировано

65
Expert consensus and recommendations on the live attenuated hepatitis A vaccine and immunization practices in India DOI Creative Commons

Nitin Shah,

MMA Faridi,

Sheila Bhave

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Янв. 16, 2025

While Hepatitis A Virus (HAV) vaccination in global immunization programs has shown a virtual elimination of the disease within few years program, changing epidemiological landscape India underscores need for evidence-based, updated guidance on practices. In May 2024, panel 15 distinguished opinion leaders and an organizing committee convened intensive, face-to-face advisory board meeting high burden HAV infection among adults, increased mortality rate adolescents, symptomatic presentation children, evolving globally India. Extensive comparable deliberations long-term follow-up data from country origin advocated immunogenicity, tolerability, protective effects single-dose live attenuated vaccine children. Finally, consensus was achieved recognition attention toward prevention through coverage. The single dose important outcome this meeting.

Язык: Английский

Процитировано

0
Global, regional, and national burden of diabetes and its risk factors in women of child-bearing age, from 1990 to 2021 DOI
Yubo Liu, Chenxi Liu, Jie Liu

и другие.

Public Health, Год журнала: 2025, Номер 241, С. 99 - 106

Опубликована: Фев. 18, 2025

Язык: Английский

Процитировано

0
Global burden and trends of viral hepatitis among women of childbearing age from 1990 to 2021 DOI Creative Commons
Shaojie Yang,

Lin Zhong,

Lu Huang

и другие.

Frontiers in Microbiology, Год журнала: 2025, Номер 16

Опубликована: Фев. 21, 2025

Background The burden and trends of viral hepatitis in women childbearing age (WCBA) are rarely quantified. This study aimed to assess the global, regional, national incidence prevalence rates among WCBA from 1990 2021. Methods From 2021, we retrieved data Global Burden Diseases, Injuries, Risk Factors Study (GBD) 2021 on A, B, C, E for WCBA. Estimated annual percent change age-standardized were calculated quantify temporal trend. Results In it was estimated that there 42,266,708 new cases 109,107,759 prevalent globally. AHA had highest rate, while CHB rate Notably, AHE emerging low-endemic regions. Generally, decreased with higher SDI levels, except AHA. Between global annually by −1.11% acute A (AHA), −1.24% AHB, −0.18% AHC, −0.34% AHE, more significant reductions observed chronic B (CHB) CHC at −1.33% −0.29%, respectively. Furthermore, continued rise lower-SDI regions, proportion younger individuals affected increased as decreased. Conclusions Although have recent decades, notable regional demographic disparities remain. These concerning especially pronounced low-SDI making essential tackle healthcare resource allocation across areas varying levels.

Язык: Английский

Процитировано

0
Seroprevalence of antibodies to hepatitis A, B and C viruses across all age groups in Chonburi Province, Thailand, 2022–2023 DOI Creative Commons
Nasamon Wanlapakorn, Jira Chansaenroj, Preeyaporn Vichaiwattana

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Март 18, 2025

Viral hepatitis is a global challenge, particularly in low- and middle-income countries. The World Health Organization aims to eliminate HBV HCV by 2030, targeting HBsAg prevalence below 0.1% children under 5. This study analyzed sera from 1,459 participants of all ages Chonburi province, Thailand, between October 2022 January 2023 assess whether this target has been met evaluate the seroprevalence anti-HBs, anti-HBc, anti-hepatitis A virus (HAV), anti-HCV population. Participants were healthy individuals with no immunosuppressed status. Results indicated 0% rate among 5, while those born before universal immunization program had 5.6%. lowest anti-HBs seropositivity (anti-HBs ≥10 mIU/mL) was observed adolescents aged 11–20 (31.7%). anti-HBc increased age, following pattern similar trends. Only small percentage subjects (0.3%) tested positive for anti-HCV. anti-HAV 20% 40. These findings suggest that Thailand regional targets 5 due high HepB vaccination coverage timely birth doses.

Язык: Английский

Процитировано

0
Global burden of viral infectious diseases of poverty based on Global Burden of Diseases Study 2021 DOI Creative Commons
Xinchen Li, Yanyan Zhang, Qiyu Zhang

и другие.

Infectious Diseases of Poverty, Год журнала: 2024, Номер 13(1)

Опубликована: Окт. 8, 2024

Viral infectious diseases of poverty (vIDPs) remain a significant global health challenge. Despite their profound impact, the burden these is not comprehensively quantified. This study aims to analyze six major vIDPs, including coronavirus disease 2019 (COVID-19), HIV/AIDS, acute hepatitis, dengue, rabies, and Ebola virus (EVD), using data from Global Burden Diseases, Injuries, Risk Factors Study 2021 (GBD 2021).

Язык: Английский

Процитировано

3
Global burden of viral infectious diseases of poverty based on GBD 2021 DOI Creative Commons

Xinchen LI,

Yanyan Zhang,

Qiyu ZHANG

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Июнь 19, 2024

Abstract Background Viral infectious diseases of poverty (vIDPs) remain a significant global health challenge. Despite their profound impact, the burden these is not comprehensively quantified. This study aims to analyze six major vIDPs, including COVID-19, HIV/AIDS, acute hepatitis, dengue, rabies, and Ebola, by using data from Global Burden Diseases, Injuries, Risk Factors Study 2021 (GBD 2021). Methods Following methodological framework analytical strategies GBD 2021, we analyzed incidence, mortality, disability-adjusted life years (DALYs) vIDPs across 204 countries territories 1990 2021. We also examined association between Socio-Demographic Index (SDI) vIDPs. All estimates were reported as numbers rates per 100,000 population, with 95% uncertainty intervals (UI). Results In total deaths due approximately 8.7 million, DALYs 259.2 accounting for 12.8% 9.0% all-cause totals, respectively. Globally, varied significantly. COVID-19 was most impactful, 7.9 million (95% UI 7.5-8.4) 212.0 197.9-234.7) in Acute hepatitis had second-highest age-standardized incidence rate, while HIV/AIDS high prevalence rate. The dengue significantly increased, cases rising 26.5 3.9-51.9) 59.0 15.5-106.9) Rabies, although reduced prevalence, continued pose mortality risk. Ebola lowest overall but showed impacts during outbreaks. Analysis revealed negative correlation SDI whereas no direct SDI. Conclusions public challenges worldwide, regional, age, gender disparities. results underscore need targeted interventions international cooperation mitigate diseases. Policymakers can use findings implement cost-effective improve outcomes, particularly regions or increasing burdens.

Язык: Английский

Процитировано

2